𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intravenous treosulfan versus intravenous treosulfan plus cis-platinum in advanced ovarian carcinoma

✍ Scribed by J Masding; TK Sarkar; WF White; VL Barley; SL Chawla; E Boesen; AY Rostom; AP Menday

Book ID
118890270
Publisher
Elsevier Science
Year
1991
Tongue
English
Weight
137 KB
Volume
34
Category
Article
ISSN
0020-7292

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

cis-platinum, adriamycin, and hexamethyl
cis-platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma
✍ J. Carmo-Pereira; F. Oliveira Costa; Elvira Henriques πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 411 KB

Fifty-three evaluable patients with disseminated ovarian carcinoma (FIGO Ill or IV) not treated with prior chemotherapy were randomized to receive either combination chemotherapy consisting of cis-platinum 40 mg/m e IV on day 1, adriamycin 40 mg/m 2 IV on day 1, and hexamethylmelamine 150 mg/m 2 PO

A Phase I trial of intravenous melphalan
A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma
✍ David M. Gershenson; Mitchell Morris; Thomas W. Burke; Charles Levenback; Judith πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 96 KB πŸ‘ 2 views

The primary purpose of this study was to establish the maximum tolerated dose (MTD) of intravenous melphalan in combination with paclitaxel and cisplatin plus granulocyte-colony stimulating factor (G-CSF) in patients with suboptimal advanced epithelial ovarian carcinoma or primary peritoneal carcino